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Running title: Identifying people at higher risk of melanoma 
 
  
:KDW¶VDOUHDG\NQRZQ about this topic?  
x Programmes to identify people at higher risk of melanoma and offer them preventive advice about 
sun protection, skin awareness, early consultation or surveillance are of increasing interest to 
healthcare providers in the UK and internationally. 
x Numerous models for predicting future risk of melanoma exist, with little difference between 
models suitable for self-assessment and those requiring a health care professional; none have been 
calibrated for the UK population. 
 
 
What does this study add? 
x Collecting data on the melanoma risk profile of the general population in UK primary care is both 
feasible and acceptable.  
x This provides an opportunity for new methods of real-time risk assessment in primary care.  
x Using the Williams model produces a distribution of risk in the population attending GP practices 
which allows identification of sub-groups at different levels of risk.  
x As regional differences were small a single approach could be implemented. 
 
  
SUMMARY 
Background 
Melanoma incidence is rising rapidly worldwide among Caucasian populations. Defining higher-risk 
populations using risk prediction models may help targeted screening and early detection approaches. 
We aimed to assess the feasibility of identifying people at higher risk of melanoma using the Williams 
self-assessed clinical risk estimation model in UK primary care. 
Methods 
We recruited participants from the waiting rooms of 22 general practices covering a total population of 
>240,000 in three UK regions: Eastern England, Northeast Scotland and North Wales. Participants 
completed an electronic questionnaire using tablet computers. The main outcome was the mean 
melanoma risk score using the Williams melanoma risk model. 
Results 
7,742 of 9,004 approached people completed the electronic questionnaire (86%). The mean melanoma 
risk score for the 7,566 eligible participants was 17.15 (SD 8.51), with small regional differences (lower 
in England compared with Scotland (p = 0.001) and Wales (p < 0.0005)), mainly due to greater freckling 
and childhood sunburn among Scottish and Welsh participants. After weighting to the age and gender 
distribution, different potential cut-offs would allow between 4% and 20% of the population to be 
identified as higher risk, and those groups would contain 30% and 60% respectively of those likely to 
develop melanoma. 
Conclusions 
Collecting data on the melanoma risk profile of the general population in UK primary care is both 
feasible and acceptable for patients in a general practice setting, and provides opportunities for new 
methods of real-time risk assessment and risk stratified cancer interventions.  
Key words: Melanoma, risk assessment, primary care 
INTRODUCTION 
Melanoma is the leading cause of skin cancer deaths in the UK, with incidence rates having increased by 
55% between 2000 and 2009 and continuing to rise (1, 2).  Identifying people at higher risk of melanoma 
can help early diagnosis and prevention, and in turn mortality (3, 4). Screening programmes to identify 
those at higher risk of melanoma and offer them preventive advice about sun protection and skin 
awareness and early consultation or surveillance are, therefore, of increasing interest to policy and 
healthcare providers.   
 
Currently mass-screening is not recommended in the UK because of difficulties in identifying the target 
population (5), plus concerns about the low incidence of melanoma and therefore the time and resources 
required to identify a relatively small number of people with the disease (6). Additionally, while the 
SCREEN project in northern Germany has suggested that population screening is feasible and may have 
an impact on diagnosis and 5 year mortality, it led to an increase in biopsies (7, 8), and there has been 
insufficient evidence for the cost-effectiveness of routine screening of the general population using a total 
body skin examination (9). Previous studies, however, suggest that selective, targeted screening might be 
more cost-effective as the cost falls dramatically when screening is targeted to higher risk populations, 
defined variously by age, family history or phenotypic characteristics (10-14). A stratified approach is 
currently recommended for Australian primary care physicians, advised to perform skin examinations 
every 3-12 months in people with multiple atypical or dysplastic naevi or a first-degree relative with 
melanoma (15).  
 
The overall impact of stratified screening for melanoma, however, depends on easily and accurately 
identifying a high-risk group (16). This may be improved by the use of risk prediction models.  Our 
recent systematic review identified 25 risk models for predicting future risk of melanoma (17). Twelve of 
those are suitable for self-assessment (defined as not including any of the following factors: dysplastic or 
atypical naevi, actinic lentigines, total body naevus count, genetic analysis requiring samples, or 
specialised equipment such as dermoscopy or colorimetry). Many had performance measures comparable 
to those for other cancers, including breast cancer (18)  and colon cancer (19), and there was little 
difference between those scores suitable for self-assessment and those requiring a health care 
professional.  The review did not identify any risk models calibrated for the UK population and none 
were more than moderately predictive. Of those suitable for self-assessment, only one developed from a 
US case-control study by Williams et al (20) had been validated outside the development population. It is 
a self-assessed clinical risk estimation model not requiring full-body skin examination that, in a 
validation population, had an area under the receiver operator characteristic curve of 0.70 (95% C.I. 0.64 
to 0.77) and was able to identify 15% of the population in whom 50% of melanomas would be expected 
to develop. The Williams score can therefore be used to determine population risk of melanoma and 
enable stratified screening based on individual risk. The aim of this study was to assess the feasibility of 
identifying people at higher risk of melanoma using the Williams self-assessed clinical risk estimation 
PRGHOWKHµ:LOOLDPVPRGHO¶ (20) in UK primary care. 
 
METHODS 
Study Population and Data Collection 
Ethical approval was gained from the West Midlands Research Ethics Committee (13/WM/0405).  
Participants were recruited from general practices in Eastern England (n=10), Northeast Scotland (n=6) 
and North Wales (n=6) between February 2014 and March 2015.  Patients and companions aged  
years were approached in general practice waiting rooms by trained researchers at different times of day 
and different days of the week; posters were also placed in the waiting rooms to advertise the study. 
Those willing to take part were invited to complete an electronic questionnaire using tablet computers. 
The gender and reason for not wishing to participate was recorded for each person choosing not to take 
part.  
 
Tablet computer-administered electronic questionnaire 
The electronic questionnaire consisted of two sections: the Williams model and additional demographic 
variables. The questions for the Williams model were phrased as originally reported (20) and included: 
gender, age, natural hair color at the age of 15, number of raised moles on both arms, density of freckles 
on both arms before the age of 20, number of severe sunburns up to the age of 18, and prior non-
melanoma skin cancer (basal-cell cancer and squamous-cell cancer). Participants were also asked 
whether they had had melanoma.  Age was collected in six age bands (20-34, 35-44, 45-54, 55-64. 65-74 
DQG years). The questions and possible responses for the other risk factors are shown in Box 1. 
Photographic images were included of raised moles and freckles alongside those questions to facilitate 
completion of the questionnaire by each participant independently. The demographic section included 
questions on ethnic group, education level, and employment status.  
 
Statistical analyses 
The risk score for each participant was calculated using the points scoring system developed by Williams 
et al. (Box 2) (20). We then computed the mean risk score and standard deviation for the entire sample 
and for each of the three regions separately, and compared the mean risk in each of the three regions 
using linear regression adjusting for the age and gender of participants. We proceeded to calculate the 
proportion of participants who would be identified as high risk using each of the four risk score cut-offs 
used by Williams et al. (25, 28, 30, and 34). We repeated this weighted to the age and gender distribution 
of the registered practice populations to obtain estimates of the proportion of the population who would 
be classified as high risk if the entire practice population had been questioned. To estimate the positive 
predictive value (PPV) and negative predictive value (NPV) for each cut-off we assumed that the 
Williams model would perform equally in the UK population as in the published validation study.  We 
used the sensitivity and specificity reported by Williams et al. for each of the four risk score cut-offs and 
the published national data for 2011 crude melanoma incidence to estimate 5 year PPVs and 5 year 
NPVs. All analyses were performed using STATA version 12. 
 
RESULTS 
General practices 
The 10 Eastern England practices had between 4,229 and 20,279 registered patients and covered a total 
population of 112,651 patients; most were urban (n = 7). The six in Northeast Scotland were mostly rural 
or semi-rural (n = 5) with between 1,845 and 20,976 registered patients covering a total population of 
68,010, and the six in North Wales were mostly urban or semi-urban (n = 5) with between 5,801 and 
15,409 registered patients covering a total population of 60,096 (Table 1).  
 
Participant recruitment 
The total person-time spent recruiting was 1009 hours, with the time in each practice ranging from 15 to 
93 hours and the mean time per participant ranging from 2.1 to 18.5 minutes (mean 8.2, SD 5.0 minutes). 
This variation was largely due to differences in patient flow within practices. Factors facilitating quicker 
recruitment included: larger practice size; a greater number of doctors in the practice at the time; larger 
waiting rooms with more space to approach patients; and longer waiting times for appointments.   
Conversely, recruitment was difficult at times when large numbers of patients were arriving for very 
short appointments, such as blood tests of flu vaccinations, as many were called in before they had time 
to complete the questionnaire. Overall, 9,004 people (3.7% of the registered population) were approached 
and 7,742 completed the electronic questionnaire (86%) (Figure 1). 275 people agreed to take part but 
were called for their appointment before completing the electronic questionnaire (3%), and 1,063 people 
(12%) declined to participate. The total number recruited from the Eastern England practices was higher 
than in Northeast Scotland or North Wales (4,140 compared to 1,509 and 2,093 respectively) but 
acceptance rates were similar in all three regions (Eastern England 85.3%, Northeast Scotland 86.8%, 
North Wales 86.7%). Reasons for not wishing to participate varied: over half either provided no reason or 
indicated no interest in the study (n = 593, 55.8%) with other common reasons including poor English (n 
= 86, 8.1%), no time (n = 72, 6.8%), and not having glasses with them (n = 59, 5.6%). 
 
Participants 
We excluded 177 (2.3%) participants (Eastern England 101, Northeast Scotland 29, North Wales 47) 
who had a history of melanoma. 7,566 participants are therefore included in further analyses. Table 2 
shows the details of these 7,566 participants by the three regions with comparison where possible to the 
total patients registered in the practices. The majority were white (British and others, 96.5%), reflecting 
the regional populations (21, 22). Our sample contained proportionately fewer male, and older, 
participants than that of registered patients in the practices. Most were retired (30.1%) or working full-
time (35.9%), and education levels were similar to those in the 2011 Office of National Statistics, with 
over a quarter having an undergraduate degree (10.4%) or postgraduate degree or professional 
qualification (16.7%).  
 
Distribution of melanoma risk factors and scores 
Table 3 shows the mean risk score in each of the three regions and for the entire study population along 
with a breakdown of the proportion with each risk factor.  The mean risk score for all 7,566 participants 
was 17.15 (Standard Deviation (SD) 8.51) and was similar in each of the three regions (Eastern England: 
mean 16.79, SD 8.47; Northeast Scotland: mean 17.87, SD 8.41; North Wales: mean 17.37, SD 8.60). 
This difference in mean scores between Northeast Scotland and Eastern England of 1.10 (95% CI 0.59 to 
1.61) reduced to 0.67 (95% CI 0.26 to 1.09, p = 0.001) after adjusting for age and gender; the 
corresponding difference between North Wales and Eastern England increased from 0.60 (95% CI 0.14 
to 1.05) to 0.80 (95% CI 0.43 to 1.18, p < 0.0005) after adjusting for age and gender. These differences 
were mostly explained by increased density of freckles on both arms before the age of 20 and a greater 
number of severe sunburns aged 2-18 years reported by participants in both Northeast Scotland and 
North Wales; the difference between Northeast Scotland and North Wales was not significant (p = 0.58). 
 
Figure 2 shows the distribution (unweighted) of melanoma risk scores in each of the three regions and the 
entire study population, overlaid with the four cut-off points used in the Williams model. Table 4 shows 
the percentage of the study participants above each of the four cut-off points used in the Williams model, 
along with the estimated percentage of the registered practice population at all the included practices 
(estimated by weighting to age and gender distribution of practice populations) above each cut-off. 
Estimated positive predictive and negative predictive values are also given for each cut-off in the three 
regions using the values for the relative risk, sensitivity and specificity reported in the Williams paper 
and assuming that the model is transferable to the UK population (20). These suggest that, for example, 
using the lowest cut-off of 25 would classify approximately 17.7% of the practice populations in Eastern 
England as higher risk. This group would contain approximately 61% of the people predicted to be 
diagnosed with a melanoma at any time in the future and approximately 3.1% of this group would be 
expected to develop melanoma in the following five years. These values are similar for Northeast 
Scotland and North Wales but a slightly greater proportion of the population would be classified as high 
risk in both regions than in Eastern England at all thresholds (Table 4).  
 
 
DISCUSSION 
To our knowledge this is the first study to use tablet computers to collect data specifically on risk of 
cancer in primary care. We have shown that collecting data on the risk profile of the general population 
in UK primary care is both feasible and acceptable. This provides an opportunity for new methods of 
real-time risk assessment in primary care for melanoma and for other cancers. We have also shown that 
using the Williams model (20) produces a distribution of risk in the population attending GP practices 
which allows identification of sub-groups at different levels of risk. Although this distribution varied 
slightly between the three regions of the UK included in this study, the differences were small and, from 
a policy perspective, suggest that a single risk stratifying approach could be implemented across the 
whole UK in the future.  
 
The main strength of this study is the method of collecting data. Over 90% of patients approached while 
attending routine general practice agreed to take part, and we were able to easily recruit 7,742 
participants from three regions across the UK with an average total researcher time per participant of less 
than 10 minutes. Furthermore, we were able to collect data from a large sample representing a general 
practice population of almost quarter of a million people, and drawn from three distinct regions across 
the UK.   
 
This data collection method, however, has its limitations. First, the recruited sample is drawn from those 
attending general practice, so we acknowledge that we may not have accessed individuals who are 
reluctant to visit their doctors, and that some selective approaching of potential participants was 
inevitable. The older people and women will tend to be over-represented as they attend general practice 
more than younger people and men (23); women are also more likely to be in the practice accompanying 
young children or more elderly people. To account for this we repeated our analysis with our sample 
weighted to the practice registered populations. This requires the assumption that the risk of developing 
melanoma in the patients not attending the practice is the same as those of the same age and gender who 
did attend the practice during the recruitment period. We think this assumption is reasonable as most 
primary care consultations are not related to melanoma or its risk factors. Our sample is also 
predominantly white (British and others) which limits the generalizability of our findings to other ethnic 
groups, many of whom would be at lower risk of melanoma. The ethnic distribution of our sample does, 
however, reflect the regional populations in the three areas where over 90% are white British, and are 
likely to be targeted in a risk stratified melanoma screening programme.     
 
Other limitations include that this was a cross-sectional study with no follow-up. The absence of 
melanoma outcomes means we are unable to assess the performance of the Williams model in this UK 
population. The estimated 5-year PPVs and NPVs are therefore based on the sensitivity and specificity of 
the different risk score cut-off values reported from the original paper by Williams et al (20). We 
acknowledge that the model was self-validated on a fairly small dataset from Washington State, USA, 
where the cases were all white and aged between 35 and 74. The performance measures reported by 
Williams et al at the different thresholds are, therefore, estimates calculated from this sample not the 
whole population. The model has also not been calibrated for the UK population. The age-standardised 
incidence of melanoma is lower in the UK than in the USA (17.3/100,000 for England in 2011 (6), 
compared to 22.86/100,000 in the USA in 2011 (24)), so the sensitivity may be slightly higher and the  
specificity slightly lower due to spectrum effect. We also excluded patients with previous melanoma 
whilst national incidence data includes all new cases of melanoma. The Williams model does not contain 
some expected risk factors such as family history of skin cancer and skin colour. Our review found that 
family history was absent in many models: it was considered in 18 of the models but only remained in 
the final score in 6 (17). Finally, most of the questions were asking either about the past and so subject to 
recall bias or required participants to count raised moles. However, the same biases would be true for the 
original Williams model which performed well in an external validation cohort and in this study we 
additionally included photographs of moles and freckles to help participants distinguish between them 
which, if anything, would be expected to improve the performance of the model.   
 
Only one similar study has been conducted for melanoma risk (25), where patients at 16 English general 
practices completed a paper questionnaire based on a risk score developed by Mackie (26). While this is, 
therefore, the first study to use tablet computers to collect melanoma, or any other cancer-specific risk 
factor information, in general practice waiting rooms, tablet computers have been used in this setting 
previously. One collected general health risk information from patients attending an Aboriginal 
Community Controlled Health Service in Australia (27), and two UK vignette-based studies have 
recently investigated ethnic differences in preferences for prostate cancer investigation (28), and for 
investigation for possible lung, colorectal and pancreatic cancer (29): both had high (>70%) recruitment 
rates. This study therefore supports the increasing interest in making the most RIWKH³ZDLWLQJURRPZDLW´, 
both for clinical practice and research.  It also identifies a number of factors to be considered when 
recruiting participants from primary care waiting rooms. In particular, the need to consider the layout of 
the waiting room and patient flow through each practice and, where possible, select times when there are 
the more appointments with GPs and less for very short consultations such as blood tests or flu 
vaccinations. However, as we did in this study, it remains important to sample at different times during 
the day to provide the opportunity to recruit a range of patient groups. For example, working individuals 
may favour early and late appointments, older patients may favour appointments in the middle of the day, 
and parents with children may favour after school appointments.  
 
This study also provides useful evidence for the planning and development of future screening and 
educational programmes in the UK for people at higher risk of melanoma. It shows that collecting 
information on risk factors in general practices across the UK is feasible and acceptable to patients, and 
that use of a melanoma risk model allows stratification of the population into different risk groups. The 
small differences in risk profiles between the three UK regions is also consistent with UK melanoma 
incidence rates which show only small and non-statistically significant differences (30) and suggests that 
a single approach could be introduced across the UK.  
 
Identifying those at higher risk in this way, therefore, could allow screening, surveillance or education 
programmes to be targeted at those most likely to benefit, including specific advice and support via 
primary care. In particular, the risk stratification could be used to determine the interval for surveillance, 
with those at higher risk being recommended to have more frequent screening. This is of particular 
relevance to conditions like melanoma where the overall incidence is low but the benefits of prevention 
or identifying people with disease earlier are substantial. The low incidence means interventions at the 
whole population level have considerable implications in terms of health care costs to benefit only a 
small number for whom early detection could improve treatment options, reduce morbidity and mortality, 
and both physical and psychological consequences to the large numbers who are unlikely to ever develop 
the condition (31).  
 
The proportion of the population in the higher risk group depends on the choice of risk cut-off point. As 
with all screening there is a trade-off between sensitivity and specificity. A cut- off with higher 
sensitivity will increase the proportion of those likely to go on to develop melanoma being identified as 
higher risk, but at the expense of a lower specificity and a larger proportion of the population classified 
as higher risk. Using the four cut-off points of the Williams model in this study would identify between 
4% and 20% of the population as candidates for a targeted intervention, and those groups would contain 
between approximately 30% and 60% respectively, of those likely to develop melanoma. This is not 
dissimilar to the 8.7% of the populaWLRQLGHQWLILHGDV³ZRUU\LQJO\KLJKULVN´RU³YHU\LQFUHDVHGULVN´LQ
the study by Jackson et al (25). While such strategies are likely to increase local referral rates and 
dermatology workload, and there is a UK shortage of dermatologists, a recent review suggests that 
melanoma early detection programmes might be cost-effective (14) if targeted at high-risk populations 
such as older men (32) or those with a family history of melanoma (12). It is likely that identifying 
higher-risk individuals using a risk score would be more cost-effective, but further studies are needed to 
confirm this and to determine the most cost effective intervals for surveillance amongst those at different 
levels of risk. 
 
The finding that collecting risk information in waiting rooms in general practices across the UK using 
tablet computers was both feasible and acceptable to patients also has implications beyond screening for 
melanoma. In addition to completing risk assessment questionnaires, patients could also: identify 
consultation goals and enable doctors to better tailor appointments; be provided with educational 
material; and complete decision aids (33). The acceptability of a self-completed tool also suggests that 
similar approaches could be used more widely in settings outside the waiting room, such as in 
pharmacies or secondary care, as well as potentially via web based applications.  
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TITLES AND LEGENDS TO FIGURES 
Figure 1. Recruitment flow chart 
Figure 2. Distribution of risk scores. Vertical lines mark the four different score cut-offs (25, 
28, 30 and 34) of the Williams model (20) melanoma risk score with the percentage of 
participants above each threshold alongside. 
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Box 1: Williams model melanoma risk score calculation (range 0-67) (20) 
Risk factor Score Risk factor Score 
Sex  Prior non-melanoma skin cancer  
Male 7 No 0 
Female 0 Yes 13 
    
Age in years  Number of raised moles on both arms  
35-44 0 None 0 
45-54 5 1 3 
55-64 8 2 5 
65-74 11 3 or more 11 
    
Natural hair colour at age 15  Density of freckles on arms before age 20  
Dark brown/black 0 None 0 
Light brown 4 A few 4 
Blond 5 Several 6 
Red 8 A lot 10 
    
Number of severe sunburns aged 2-18    
None 0   
1-4 1   
5-9 4   
10 or more 7   
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Table 1: Characteristics of General Practices 
 
 Practice 
type 
Practice 
populationa 
Cancer 
prevalenceb 
Deprivation  
(IMD quintile)c 
Number 
recruited 
Eastern England      
 Urban 20,279 2.1 3 422 
 Urban 17,657 2.8 2 392 
 Urban 11,396 3.0 3 395 
 Rural 11,129 2.1  1 436 
 Rural 10,517 1.8  1 300 
 Rural 10,408 2.1 2 396 
 Urban 9,549 2.2 1 433 
 Urban 9,115 2.2  2 458 
 Urban 8,372 2.4 3 396 
 Urban 4,229 2.7 4 409 
North East Scotland      
 Semi-rural 20,976 2.1 2 431 
 Semi-rural 15,726 2.2 3 326 
 Semi-rural 12,222 2.8 1 150 
 Urban 11,062 1.9 5 368 
 Rural 6,179 2.4 2 122 
 Rural 1,845 1.6 1 83 
North Wales      
 Semi urban 15,409 2.4 2 387 
 Urban 13,068 2.4 3 384 
 Urban 9,935 2.8 4 195 
 Rural 8,331 2.8 2 502 
 Semi urban 7,552 0.6 4 236 
 Semi urban 5,801 2.2 2 342 
 
a At time of recruitment 
b
 Prevalence data in the Quality and Outcomes Framework: percentage of patients with a diagnosis of cancer, excluding non-
melanotic skin cancer. England and Wales 2013-2014 from www.gpcontract.co.uk and Scotland 2012-2013 from 
www.isdscotland.org.qof   
c
 Index of Multiple Deprivation (IMD) quintiles computed using the practice postcode and published values for IMD where 
1 is the least deprived. 
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Table 2: Sociodemographic characteristics of participants 
 
Characteristic Eastern 
England 
n (%) 
Northeast 
Scotland 
n (%) 
North Wales 
n (%) 
Total 
n (%) 
Population > 20 
years registered 
at all practices 
 n (%) 
Gender      
Male  1399 (34.6) 517 (34.9) 775 (37.9) 2691 (35.6) 91,593 (49.5) 
Female 2641 (65.4) 963 (65.1) 1271 (62.1) 4875 (64.4) 93,560 (50.5) 
Age in years      
20-35 years 916 (22.7) 298 (20.1) 567 (27.7) 1781 (23.5) 43,286 (23.4) 
35-44 years 692 (17.1) 218 (14.7) 335 (16.3) 1245 (16.5) 32,500 (17.5) 
45-54 years 671 (16.6) 238 (16.1) 351 (17.2) 1260 (16.7) 35,804 (19.3) 
55-64 years 611 (15.1) 264 (17.8) 325 (15.9) 1200 (15.9) 29,245 (15.8) 
65-74 years 630 (15.6) 260 (17.6) 317 (15.5) 1207 (16.0) 24,374 (13.2) 
\HDUV 520 (12.9) 202 (13.6) 151 (7.4) 873 (11.5) 19,944 (10.8) 
Ethnic group      
White British 3620 (89.6) 1372 (92.7) 1945 (95.1) 6937 (91.7) --- 
White other 224 (5.5) 75 (5.1) 63 (3.1) 362 (4.8) --- 
Mixed  27 (0.7) 9 (6.1) 5 (0.2) 41 (0.5) --- 
Asian or Asian British 87 (2.2) 9 (6.1) 12 (0.6) 108 (1.4) --- 
Black or Black British 35 (0.9) 5 (0.3) 7 (0.3) 47 (0.6) --- 
Chinese 12 (0.3) 2 (0.1) 5 (0.2) 19 (0.3) --- 
Other ethnic group 35 (0.8) 8 (0.5) 9 (0.4) 52 (0.7) --- 
Education      
None 719 (17.8) 295 (19.9) 349 (17.1) 1363 (18.0) --- 
GCSE, O Level or CSE 975 (24.1) 285 (19.2) 528 (25.8) 1788 (23.6) --- 
Vocational 684 (16.9) 293 (19.8) 387 (18.9) 1364 (18.0) --- 
A Level or equivalent 570 (14.1) 162 (10.9) 271 (13.2) 1003 (13.3) --- 
Undergraduate degree 386 (9.6) 190 (12.8) 210 (10.3) 786 (10.4) --- 
Postgraduate degree or 
professional qualification 706 (17.5) 255 (17.2) 301 (14.7) 1262 (16.7) 
--- 
Employment status      
Retired 1276 (31.6) 481 (32.5) 517 (25.3) 2274 (30.1) --- 
Unemployed, seeking work 99 (2.5) 29 (2.0) 63 (3.1) 191 (2.5) --- 
Unemployed, unable to work 63 (1.6) 23 (1.6) 72 (3.5) 158 (2.1) --- 
Student 67 (1.7) 54 (3.6) 64 (3.1) 185 (2.4) --- 
Working part-time 778 (19.3) 288 (19.5) 331 (16.2) 1397 (18.5) --- 
Working full-time 1393 (34.5) 472 (31.9) 849 (41.5) 2714 (35.9) --- 
Home Carer/Homemaker 308 (7.6) 97 (6.6) 100 (4.9) 505 (6.7) --- 
Permanently sick or disabled 56 (1.2) 36 (2.4) 50 (2.4) 142 (1.9) --- 
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Table 3. Risk factor profile of participants 
 
Risk factor Point 
score 
Eastern 
England 
n (%) 
Northeast 
Scotland 
n (%) 
North Wales 
n (%) 
All 
n (%) 
Sex      
Male 7 1399 (34.6) 517 (34.9) 775 (37.9) 2691 (35.6) 
Female 0 2641 (65.4) 963 (65.1) 1271 (62.1) 4875 (64.4) 
 
     
Age in years      
<44 0 1608 (39.8) 516 (34.8) 902 (44.0) 3026 (40.0) 
45-54 5 671 (16.6) 238 (16.1) 351 (17.2) 1260 (16.7) 
55-64 8 611 (15.1) 264 (17.8) 325 (15.9) 1200 (15.9) 
>65 11 1150 (28.5) 462 (31.2) 468 (22.9) 2080 (27.5) 
 
     
Natural hair colour at age 15      
Dark brown/black 0 1,518 (37.6) 579 (39.1) 811 (39.6) 2,908 (38.4) 
Light brown 4 1,634 (40.4) 574 (38.8) 830 (40.6) 3,038 (40.2) 
Blond 5 718 (17.8) 230 (15.5) 306 (15.0) 1,254 (16.6) 
Red 8 170 (4.2) 97 (6.6) 99 (4.8) 366 (4.8) 
      
Number of severe sunburns aged 2-18      
None 0 2,111 (52.2) 698 (47.2) 892 (43.6) 3,701 (48.9) 
1-4 1 1,623 (40.2) 609 (41.1) 964 (47.1) 3,196 (42.2) 
5-9 4 197 (4.9) 94 (6.4) 121 (5.9) 412 (5.5) 
10 or more 7 109 (2.7) 79 (5.3) 69 (3.4) 257 (3.4) 
      
Prior non-melanoma skin cancer      
No 0 3,930 (97.3) 1,457 (98.4) 1,996 (97.6) 7,383 (97.6) 
Yes 13 110 (2.7) 23 (1.6) 50 (2.4) 183 (2.4) 
      
Number of raised moles on both arms      
None  0 2,654 (65.7) 1,020 (68.9) 1,298 (63.4) 4,972 (65.7) 
1 3 618 (15.3) 163 (11.0) 279 (13.6) 1,060 (14.0) 
2 5 312 (7.7) 123 (8.3) 202 (9.9) 637 (8.4) 
3 or more  11 456 (11.3) 174 (11.8) 267 (13.1) 897 (11.9) 
      
Density of freckles on arms before age 20      
None 0 1,793 (44.4) 591 (40.0) 707 (34.6) 3.091 (40.9) 
A few 4 1,309 (32.4) 481 (32.5) 792 (38.7) 2,582 (34.1) 
Several 6 518 (12.8) 159 (10.7) 261 (12.7) 938 (12.4) 
A lot 10 420 (10.4) 249 (16.8) 286 (14.0) 955 (12.6) 
      
Total score (mean (sd))  16.8 (8.5) 17.9 (8.4) 17.4 (8.6) 17.1 (8.5) 
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Table 4: The population above various risk score cut-offs of the Williams model melanoma risk 
score (20) along with the estimated positive predictive and negative predictive values 
 
 
 
a Weighted for the age and gender of the registered population in each participating practice 
b
 Estimated 5-yr PPV ± the estimated proportion of the population considered higher risk who would be diagnosed with 
melanoma in the next 5 years, assuming the same performance of the Williams model as reported in Williams et al 2011 and 
a prevalence of newly diagnosed cases of 104.5/100,000 for England (the 2011 crude incidence of melanoma in England 
from data from the Office of National Statistics multiplied by 5), 119/100,000 for Wales (the 2011 crude incidence of 
melanoma in Wales from the Welsh Cancer Intelligence and Surveillance Unit) and 114.5/100,000 for Scotland (the 2011 
crude incidence of melanoma in Scotland from the Cancer Information Programme, Information Services Division Scotland) 
c
 Estimated 5-yr NPV - the estimated proportion of the population considered low risk who would not be diagnosed with 
melanoma in the next 5 years, assuming the same performance of the Williams model as reported in Williams et al 2011 and 
a prevalence of newly diagnosed cases of 104.5/100,000 for England (the 2011 crude incidence of melanoma in England 
from data from the Office of National Statistics multiplied by 5), 119/100,000 for Wales (the 2011 crude of melanoma in 
Wales from the Welsh Cancer Intelligence and Surveillance Unit) and 114.5/100,000 for Scotland (the 2011 crude incidence 
of melanoma in Scotland from the Cancer Information Programme, Information Services Division Scotland) 
Region :LOOLDPV¶
Risk score 
cut-off 
Sample above 
cut-off (%) 
Practice 
population 
above cut-off 
(%)a 
Estimated 5-yr 
PPV (%)b 
Estimated 5-yr 
NPV (%)c 
Eastern England 25 16.5 17.7 3.1 99.5 
 28 10.3 11.0 3.4 99.4 
 30 7.4 7.9 4.3  99.3 
 34 3.1 3.5 5.7 99.2 
Northeast Scotland 25 20.8 22.4 3.4 99.4 
 28 12.7 12.9 3.7 99.3 
 30 9.6 9.8 4.7 99.3 
 34 3.2 3.6 6.2 99.1 
North Wales 25 18.5 19.3 3.7 99.4 
 28 11.3 12.2 3.9 99.3 
 30 8.1 8.5 4.8 99.2 
 34 3.7 4.9 6.3 99.1 
All 25 17.9 19.4 --- --- 
 28 11.0 11.8 --- --- 
 30 8.0 8.6 --- --- 
 34 3.9 3.9 --- --- 
